Health
Novel breast cancer therapy candidate enters clinical study – Mirage News
Kiran Dhillon In a UW Medicine cancer immunotherapy lab, research scientist Nick Drovetto puts a rack of samples into a liquid nitrogen tank. A Phase 1…
A Phase 1 patient trial of the novel, oral therapy candidate, Alpha TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin.
In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the HER2protein that drives cancer growth and spread.
Alpha TEA lysine…
-
Noosa News21 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business22 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News20 hours agoAfter Hours Gallery Visits, French Dining and Garden Illuminations: Your Guide to the Ultimate Melbourne Culture Fix
-
General18 hours agoDeath of 86-year-old driver in Karoonda Highway crash prompts push for change